Focused ultrasound offers the potential to treat many cancers through noninvasively destroying malignant tissue or enhancing adjuvant therapies, such as chemotherapy, radiation, or immunotherapies.
The technology is approved in Europe and the US to relieve the pain associated with bone metastases and treat prostate diseases including prostate cancer.
Focused ultrasound is also approved in Europe to treat patients with breast, liver, pancreatic and kidney cancers and soft tissue tumors.
In addition, there is significant research activity around the globe assessing the potential of the technology to enhance the delivery and effectiveness of cancer drugs.
Learn more about focused ultrasound for:
